Targeting Bcl-2 protein in treatment of melanoma still requires further clarifications

Annals of Oncology

Volumn 19, Issue 12, 2008, Pages 2092-2093

  Pisano, M ^a   Baldinu, P ^a   Sini, M C ^a   Ascierto, P A ^b   Tanda, F ^c   Palmieri, G ^a  

^a Istituto di Chimica Biomolecolare Consiglio Nazionale Ricerche   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF SASSARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; DACARBAZINE; ETOPOSIDE; OBLIMERSEN; PROTEIN BCL 2; PROTEIN TYROSINE KINASE INHIBITOR;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CANCER SURVIVAL; CLINICAL TRIAL; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG TARGETING; HUMAN; LETTER; MELANOMA; MELANOMA CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN TARGETING;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MELANOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; THIONUCLEOTIDES;

EID: 56749163582     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn672     Document Type: Letter

References (5)

1. Sosman JA, Puzanov I. Molecular targets in melanoma from angiogenesis to apoptosis. Clin Cancer Res 2006; 12: 2376s-2383s.
2. Jansen B, Wacheck V, Heere-Ress E et al. Chemosensitisation of malignant melanoma by Bcl-2 antisense therapy. Lancet 2000; 356: 1728-1733.
3. Bedikian AY, Millward M, Pehamberger H et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006; 24: 4738-4745.
4. Verweij J, de Jonge M. Multitarget tyrosine kinase inhibition: [and the winner is.]. J Clin Oncol 2007; 25: 2340-2342.
5. Benimetskaya L, Ayyanar K, Kornblum N et al. Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro. Clin Cancer Res 2006; 12: 4940-4948.